The survival analysis in the different patients’ sub-groups showed that high expression of MRPS12 was associated to a worse prognosis in the RH+ and triple-negative BC patients, while NDFUS6 was associated with a worse prognosis only in RH + BC patients. The gene discussed is MRPS12; the disease is breast cancer.